TIDMSNG
Synairgen plc
05 September 2022
Synairgen plc
('Synairgen' or the 'Company')
Synairgen announces its collaboration on the UNIVERSAL trial, an
observational study of patients hospitalised due to a range of
respiratory viruses
-- Led by the Clinical Trials Unit at the University of
Southampton, supported by Synairgen and funded by Janssen
-- Will explore the varied nature of acute respiratory viral
infections in hospitalised patients to inform the development of
much-needed broad spectrum antiviral drugs
Southampton, UK - 5 September 2022: Synairgen plc (LSE: SNG),
the respiratory company developing SNG001, an investigational
formulation for inhalation containing the broad-spectrum antiviral
protein interferon beta, today announces its collaboration on the
UNIVERSAL trial, an observational study being led by the Clinical
Trials Unit of the University of Southampton to explore and better
understand the varied nature of acute respiratory viral infection
and recovery seen in patients admitted to hospital with respiratory
symptoms.
The Understanding Infection, Viral Exacerbation and Respiratory
Symptoms at Admission-Longitudinal (UNIVERSAL) trial seeks to
develop a prospective longitudinal clinical database of respiratory
viral infections in hospitalised patients to inform the development
of potential antivirals to treat severe viral lung infections
caused by seasonal viruses and emerging viral threats. Patients
admitted to hospital due to a range of different respiratory
viruses will be sampled to determine the clinical and biological
predictors of progression of disease, recovery and length of
hospital stay. As an observational study, no treatments are being
investigated.
The trial, which aims to recruit 1,000 patients, will be
initiated at 10 sites across the UK following enrolment of its
first patient which occurred on 1 September 2022. Viral testing
equipment already owned by Synairgen and nursing staff at the
Southampton clinical trial site are being provided by Synairgen,
funding for the trial is being provided by Janssen.
Richard Marsden, CEO of Synairgen, commented: "The COVID-19
pandemic highlighted the important link between research and
clinical care and its impact on the timely development of
much-needed antivirals for severe lung viral infections caused by
seasonal viruses and emerging respiratory viral threats. Our
collaboration on the UNIVERSAL trial will help provide a better
understanding of what could predict clinical outcomes in patients
hospitalised with respiratory symptoms due to infection with a
range of respiratory viruses. The UNIVERSAL trial will help to
further inform the development programme of SNG001, our
investigational broad-spectrum antiviral."
Prof. Tom Wilkinson, Lead investigator of the UNIVERSAL trial
and Professor of Respiratory Medicine, University of Southampton,
added: "As seen over the course of the pandemic, individual
response to respiratory virus infection is variable from patient to
patient, ranging from mild symptoms requiring no treatment to
severe illness requiring higher levels of care. This observation
highlights the need for a study like UNIVERSAL to better understand
this patient journey to enable for the development of effective
therapeutics for respiratory viral illness beyond COVID."
For further enquiries, please contact:
Synairgen plc
Brooke Clarke, Head of Communications
Media@synairgen.com
Tel: + 44 (0) 23 8051 2800
finnCap (NOMAD and Joint Broker)
Geoff Nash, Charlie Beeson (Corporate Finance)
Alice Lane, Sunil de Silva (ECM)
Tel: + 44 (0) 20 7220 0500
Numis Securities Limited (Joint Broker)
James Black, Freddie Barnfield, Duncan Monteith
Tel: + 44 (0) 20 7260 1000
Consilium Strategic Communications (Financial Media and Investor
Relations)
Mary-Jane Elliott, Namrata Taak, Lucy Featherstone
cscsynairgen@consilium-comms.com
Tel: +44 (0) 20 3709 5700
MKC STRATEGIES, LLC (US Media Relations)
Mary Conway
MConway@MKCStrategies.com
Tel: +1 516-606-6545
Notes for Editors
About the UNIVERSAL trial
The Understanding Infection, Viral Exacerbation and Respiratory
Symptoms at Admission-Longitudinal (UNIVERSAL) trial is an
observational study led by the Clinical Trials Unit of the
University of Southampton, supported by Synairgen and funded by
Janssen, to explore the varied nature of acute respiratory viral
infection and recovery seen in patients admitted to hospital with
respiratory symptoms. The trial will be initiated across 10 sites
in the UK and seek to enrol 1000 patients, where 1000 test positive
for respiratory viral infection, over a 12-month period. The
primary endpoints of the trial are to determine the incidence of
different respiratory viruses in admitted, sampled patient
population during the winter season and, the clinical and
biological predictors of progression of disease, recovery and
length of stay.
The trial will provide a better understanding of the natural
history of acute respiratory viral infection and recovery to
facilitate improved clinical management with the potential to
identify options for intervention in those at risk of more severe
disease.
About Synairgen
Synairgen is a UK-based respiratory company focused on drug
discovery, development and commercialisation. The Company's primary
focus is developing SNG001 (inhaled interferon beta) for the
treatment of severe viral lung infections, including COVID-19, as
potentially the first host-targeted, broad-spectrum antiviral
treatment delivered directly into the lungs. SNG001 has been
granted Fast Track status from the US Food and Drug Administration
(FDA). Founded by University of Southampton Professors Sir Stephen
Holgate, Donna Davies and Ratko Djukanovic in 2003, Synairgen is
quoted on AIM (LSE: SNG). For more information about Synairgen,
please see www.synairgen.com .
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRABKQBQFBKDPCK
(END) Dow Jones Newswires
September 05, 2022 02:00 ET (06:00 GMT)
Synairgen (LSE:SNG)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Synairgen (LSE:SNG)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
